Doldi, Philipp; Stolz, Lukas; Orban, Mathias; Karam, Nicole; Praz, Fabien; Kalbacher, Daniel; Lubos, Edith; Braun, Daniel; Adamo, Marianna; Giannini, Cristina; Melica, Bruno; Näbauer, Michael; Higuchi, Satoshi; Wild, Mirjam; Neuss, Michael; Butter, Christian; Kassar, Mohammad; Petrescu, Aniela; Pfister, Roman; Iliadis, Christos; ... (2022). Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation. JACC. Cardiovascular imaging, 15(11), pp. 1843-1851. Elsevier 10.1016/j.jcmg.2022.05.009
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
1-s2.0-S1936878X22003436-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (670kB) |
BACKGROUND
Among patients with severe functional mitral regurgitation (FMR), atrial functional MR (aFMR) represents an underrecognized entity. Data regarding outcomes after mitral valve transcatheter edge-to-edge repair (M-TEER) in aFMR remain scarce.
OBJECTIVES
The objective was to analyze the outcome of aFMR patients undergoing M-TEER.
METHODS
Using patients from the international EuroSMR (European Registry of Transcatheter Repair for Secondary Mitral Regurgitation) registry undergoing M-TEER for FMR, we analyzed baseline characteristics and 2-year outcomes in aFMR in comparison to non-aFMR and ventricular FMR. Additionally, the impact of right ventricular dysfunction (RVD, defined as right ventricular to pulmonary artery uncoupling) on outcome after M-TEER was assessed.
RESULTS
Among 1,608 FMR patients treated by M-TEER, 126 (7.8%) were categorized as aFMR. All 126 aFMR patients had preserved left ventricular function without regional wall motion abnormalities, left arterial dilatation and Carpentier leaflet motion type I. Procedural success (defined as mitral regurgitation ≤2+ at discharge) was 87.2% (P < 0.001) and New York Heart Association (NYHA) functional class significantly improved during follow-up (NYHA class III/IV: 86.5% at baseline to 36.6% at follow-up; P < 0.001). The estimated 2-year survival rate in aFMR patients was 70.4%. Two-year survival did not differ significantly between aFMR, non-aFMR and ventricular FMR. Besides NYHA class IV, RVD was identified as strong independent predictor for 2-year survival (HR: 2.82 [95% CI: 1.24-6.45]; P = 0.014).
CONCLUSIONS
aFMR is a frequent cause of FMR and can be effectively treated with M-TEER to improve symptoms at follow-up. Advanced heart failure symptoms and RVD were identified as important risk factors for survival in aFMR patients.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology |
UniBE Contributor: |
Praz, Fabien Daniel, Kassar, Mohammad, Windecker, Stephan |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1936-878X |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
18 Jul 2022 10:06 |
Last Modified: |
05 Dec 2022 16:21 |
Publisher DOI: |
10.1016/j.jcmg.2022.05.009 |
PubMed ID: |
35842361 |
Uncontrolled Keywords: |
atrial functional mitral valve regurgitation congestive heart failure mitral valve transcatheter edge-to-edge valve repair right ventricular dysfunction secondary mitral valve regurgitation |
BORIS DOI: |
10.48350/171357 |
URI: |
https://boris.unibe.ch/id/eprint/171357 |
Actions (login required)
 |
Edit item |